OncoMatch/Clinical Trials/NCT06634966
Segmentectomy for Solid-dominant Lung Cancer
Is NCT06634966 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for segmentectomy.
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1025. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for solid-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are: * The 5-year disease-free survival of patients having solid-dominant invasive lung cancer with size of 2-3cm; * The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage CN0
cN0 without distant metastasis
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: lung cancer surgery
Cannot have received: chemotherapy
Cannot have received: radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify